Ceftolozan / Tazobactam (6) (Zerbaxa®) – Bacterial infections, multiple indications
|INN||Ceftolozan / Tazobactam|
|Pharm. company||MSD Sharp & Dohme GmbH|
|G-BA procedure ID||2022-05-01-D-815|
|Therapeutic area||Infectious diseases|
|Reason for procedure||Initial assessment – Reserve antibiotic|
|Regulatory status||Reserve antibiotic|
|G-BA resolution "Anwendungsgebiet des Beschlusses" (German)|
Zerbaxa is indicated for the treatment of the following infections in adult and pediatric patients:
Complicated intra-abdominal infections;
Complicated urinary tract infections.
Zerbaxa is also indicated in adults for the treatment of the following infection in adult patients (18 years of age and older):
Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP).
|b)||Adults with acute pyelonephritis|
|c)||Adults with complicated urinary tract infection|
|d)||Adults with hospital-acquired pneumonia, including ventilator-associated pneumonia|
9. Associated procedures
<< List of all resolutions
The AMNOG monitor is a subscription-based service for pharmaceutical manufacturers and institutions. Enter your account details here in order to analyse the results of the early benefit assessment in Germany – or contact us for more information.